1. BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492.
2. LeeJH, KimSH, SuhYJ, ShimBY, KimHK. Predictors of Axillary Lymph Node Metastases
(ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer
has a High Incidence of ALNM Irrespective of the Tumor Size. Cancer Res Treat. 2010;42:30.
doi:10.4143/crt.2010.42.1.30.
3. AbeO, AbeR, EnomotoK, KikuchiK, KoyamaH, MasudaH, et al. Effects of chemotherapy
and hormonal therapy for early breast cancer on recurrence and 15-year survival: An
overview of the randomised trials. Lancet. 2005;365:1687–717. doi:10.1016/S0140-6736(05)66544-0.
4. HungM-C, GuptaS, RezaeianAH, SunY, WeiY, MaL, et al. LIFR is a breast cancer metastasis
suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18:1511–7.
doi:10.1038/nm.2940.
5. Gonzalez-AnguloAM, Ferrer-LozanoJ, Stemke-HaleK, SahinA, LiuS, BarreraJA, et al.
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol
Cancer Ther. 2011;10:1093–101. doi:10.1158/1535-7163.mct-10-1089.
6. Charafe-JauffretE, GinestierC, IovinoF, TarpinC, DiebelM, EsterniB, et al. Aldehyde
dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome
in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55. doi:10.1158/1078-0432.CCR-09-1630.
7. TelliML. Triple-negative breast cancer. Mol Pathol Breast Cancer. 2016;363:71–80.
doi:10.1007/978-3-319-41761-5_6.
8. AkramiM, TahmasebiS, ZangouriV, HosseiniS, TaleiA. Metastatic Behavior of Breast
Cancer Subtypes. Multidiscip Cancer Investig. 2017;1 Supplementary 1:0–0. doi:10.21859/mci-supp-102.
9. TranB, BedardPL. Luminal-B breast cancer and novel therapeutic targets. Breast
Cancer Research. 2011;13. doi:10.1186/bcr2904.
10. MalikF, IthimakinS, DayK, IgnatoskiK, ZenQ, ThomasD, et al. Abstract 3470: HER2
drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications
for efficacy of adjuvant trastuzumab. Cancer Res. 2012;72 8 Supplement:3470–3470.
doi:10.1158/1538-7445.am2012-3470.
11. NadjiM, Gomez-FernandezC, Ganjei-AzarP, MoralesAR. Immunohistochemistry of estrogen
and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am
J Clin Pathol. 2005;123:21–7. doi:10.1309/4WV79N2GHJ3X1841.
12. Harvey JM, Clark GM, Osborne CKAD. Estrogen receptor status by immunohistochemistry
is superior to ligand binding assay for predicting response to adjuvant therapy in
breast cancer. J Clin Oncol. 1999;17:1474–81.
13. CarlsonRW, MoenchSJ, HammondME, PerezEA, BursteinHJ, AllredDC, et al. HER2 testing
in breast cancer: NCCN Task Force report and recommendations. J NatlComprCancNetw.
2006;4 Suppl 3:S1-22.
14. TsaoMN, RadesD, WirthA, LoSS, DanielsonBL, GasparLE, et al. Radiotherapeutic and
surgical management for newly diagnosed brain metastasis(es): An American Society
for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210–25.
doi:10.1016/j.prro.2011.12.004.
15. TobiasJ, ChilukuriR, KomatsoulisGA, MohantyS, SioutosN, WarzelDB, et al. The CAP
cancer protocols – a case study of caCORE based data standards implementation to integrate
with the Cancer Biomedical Informatics Grid. BMC Med Inform Decis Mak. 2006;6:25.
doi:10.1186/1472-6947-6-25.
16. CasatiB, HauglandHK, BarstadGMJ, BjugnR. Implementation and use of electronic
synoptic cancer reporting: An explorative case study of six Norwegian pathology laboratories.
Implement Sci. 2014;9:111. doi:10.1186/s13012-014-0111-2.
17. LeongASY. Synoptic/checklist reporting of breast biopsies: Has the time come?
Breast J. 2001;7:271–4.
18. SrigleyJR, McgowanT, MacleanA, RabyM, RossJ, KramerS, et al. Standardized synoptic
cancer pathology reporting: A population-based approach. Journal of Surgical Oncology.
2009;99:517–24. doi:10.1002/jso.21282.
19. ChangKP, ChuYW, WangJ. Analysis of hormone receptor status in primary and recurrent
breast cancer via data mining pathology reports. Open Med. 2019;14:91–8. doi:10.1515/med-2019-0013.
20. SavovaGKG, MasanzJJ, OgrenPVP, ZhengJ, SohnS, Kipper-SchulerKC, et al. Mayo clinical
Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation
and applications. J Am Med Informatics Assoc. 2010;17:507–13. doi:10.1136/jamia.2009.001560.
21. AronsonAR. Effective mapping of biomedical text to the UMLS Metathesaurus: the
MetaMap program. In: Proceedings. AMIA Symposium. 2001. p. 17–21. doi:D010001275 [pii].
22. LuoY. Towards Unified Biomedical Modeling with Subgraph Mining and Factorization
Algorithms. Massachusetts Institute of Technology; 2014.
23. LuoY, SohaniAR, HochbergEP, SzolovitsP. Automatic lymphoma classification with
sentence subgraph mining from pathology reports. J Am Med Inform Assoc. 2014;21:1–9.
doi:10.1136/amiajnl-2013-002443.
24. BermanJJ. Concept-match medical data scrubbing: How pathology text can be used
in research. Arch Pathol Lab Med. 2003;127:680–6. doi:10.1043/1543-2165(2003)127<680:CMDS>2.0.CO;2.
25. NassifH, WoodsR, BurnsideE, AyvaciM, ShavlikJ, PageD. Information Extraction for
Clinical Data Mining: A Mammography Case Study. In: 2009 IEEE International Conference
on Data Mining Workshops. 2009. p. 37–42. doi:10.1109/ICDMW.2009.63.
26. NeamatullahI, DouglassMM, LehmanLH, ReisnerA, VillarroelM, LongWJ, et al. Automated
de-identification of free-text medical records. BMC Med Inform Decis Mak. 2008;8:32.
doi:10.1186/1472-6947-8-32.
27. RossumGV. The Python Language Reference Manual, Release 3.5.1. Network Theory;
2003.
29. FitzgibbonsPL, MurphyDA, HammondMEH, AllredDC, ValensteinPN. Recommendations for
validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol
Lab Med. 2010;134:930–5. doi:10.1043/1543-2165-134.6.930.
30. WolffAC, HammondMEH, HicksDG, DowsettM, McShaneLM, AllisonKH, et al. Recommendations
for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society
of Clinical Oncology/College of American Pathologists Clinical Practice Guideline
Update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/JCO.2013.50.9984.
31. NguyenPL, TaghianAG, KatzMS, NiemierkoA, Abi RaadRF, BoonWL, et al. Breast cancer
subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated
with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26.
doi:10.1200/JCO.2007.14.4287.
32. Savci-HeijinkCD, HalfwerkH, HooijerGKJ, HorlingsHM, WesselingJ, van deVijverMJ.
Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer
Res Treat. 2015;150:547–57. doi:10.1007/s10549-015-3352-0.
33. HurJ, SchuylerAD, StatesDJ, FeldmanEL. SciMiner: Web-based literature mining tool
for target identification and functional enrichment analysis. Bioinformatics. 2009;25:838–40.
34. YangH, SpasicI, KeaneJA, NenadicG. A Text Mining Approach to the Prediction of
Disease Status from Clinical Discharge Summaries. J Am Med Informatics Assoc. 2009;16:596–600.
36. LuoY, XinY, HochbergE, JoshiR, UzunerO, SzolovitsP. Subgraph augmented non-negative
tensor factorization (SANTF) for modeling clinical narrative text. J Am Med Informatics
Assoc. 2015;22:1009–19. doi:10.1093/jamia/ocv016.